Wen Xijiao, Huang Bowan, Liang Xin
Department of Anesthesiology, Central People's Hospital of Zhanjiang Zhanjiang 524045, Guangdong, China.
Am J Transl Res. 2021 Jun 15;13(6):7001-7007. eCollection 2021.
To investigate the application value of ropivacaine combined with sufentanil for epidural labor analgesia in painless labor.
A total of 157 cases of pregnant female received painless labor in our hospital from January 2019 to December 2020 were randomly divided into observation group (n=81 cases) and control group (n=76 cases). The subjects in the observation group received 0.1% ropivacaine combined with sufentanil (0.25 μg/ml) 10 ml and added into the painless delivery pump, and the control group received 0.1% ropivacaine 10 ml into the painless delivery pump. The analgesic effect, lactation function, delivery outcomes and the labor course of the two groups were compared.
In the active stage of labor, the time of first labor process was shorter compared with the control group, those in the observation group were more active than the control group (P<0.05). The lactation initiation time of the observation group was shorter than that of the control group, and the effective rate of lactation was higher than that of the control group (P<0.05). The Visual analogue scale (VAS) score at 5 min, 30 min, 60 min, and 90 min after analgesia were improved in the observation group, the analgesic effect of ropivacaine combined with sufentanil for epidural labor analgesia was prior to ropivacaine alone. There were significant differences in the rates of conversion to cesarean section and usage rate of forceps between the two groups (P<0.05), while there had no significant differences in lateral episiotomy rate and Apgar scores at 1 and 5 min after birth between the two groups (P>0.05).
Ropivacaine combined with sufentanil for epidural labor analgesia in painless labor can effectively relieve labor pain, improve lactation function, active the first stage of labor, shorten the time of labor, reduce the incidence of cesarean section and ensure the safety of mother and infant.
探讨罗哌卡因联合舒芬太尼用于无痛分娩硬膜外分娩镇痛的应用价值。
选取2019年1月至2020年12月在我院接受无痛分娩的157例孕妇,随机分为观察组(n = 81例)和对照组(n = 76例)。观察组受试者接受0.1%罗哌卡因联合舒芬太尼(0.25μg/ml)10ml注入无痛分娩泵,对照组接受0.1%罗哌卡因10ml注入无痛分娩泵。比较两组的镇痛效果、泌乳功能、分娩结局及产程。
在产程活跃期,观察组首次产程时间较对照组短,观察组产妇较对照组活跃(P<0.05)。观察组泌乳开始时间短于对照组,泌乳有效率高于对照组(P<0.05)。观察组镇痛后5min、30min、60min、90min的视觉模拟评分(VAS)均改善,罗哌卡因联合舒芬太尼用于硬膜外分娩镇痛的效果优于单用罗哌卡因。两组剖宫产率和产钳使用率差异有统计学意义(P<0.05),而两组侧切率及出生后1min和5min的阿氏评分差异无统计学意义(P>0.05)。
罗哌卡因联合舒芬太尼用于无痛分娩硬膜外分娩镇痛可有效减轻分娩疼痛,改善泌乳功能,活跃产程第一阶段,缩短产程时间,降低剖宫产发生率,确保母婴安全。